ATG17 — RB1CC1/FIP200
Introduction
Mermaid diagram (expand to render)
ATG17 (also known as RB1CC1 or FIP200) encodes a critical scaffold protein in the autophagy initiation machinery. Formerly named ATG17 (Autophagy Related 17), the gene was renamed RB1CC1 (RB1 Inducible Coiled-Coil 1) due to its discovery as a RB1 tumor suppressor-interacting protein, while FIP200 (Focal Adhesion Kinase Family Interacting Protein of 200 kDa) remains a widely used alternate name. This protein forms the backbone of the ULK1 complex that nucleates autophagosome formation, making it essential for cellular homeostasis and survival["@rubinsztein2022"].
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">RB1CC1/FIP200/ATG17</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ATG17 (RB1CC1)</td></tr>
<tr><td><strong>Full Name</strong></td><td>RB1 Inducible Coiled-Coil 1</td></tr>
<tr><td><strong>Chromosome</strong></td><td>8q11.23</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[9881](https://www.ncbi.nlm.nih.gov/gene/9881)</td></tr>
<tr><td><strong>OMIM</strong></td><td>604791</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000055118</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q8TF72](https://www.uniprot.org/uniprot/Q8TF72)</td></tr>
<tr><td><strong>Protein Class</strong></td><td>Scaffold Protein / Autophagy Initiation</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), ALS, FTD, Cancer</td></tr>
</table>
</div>
Gene Structure and Protein Architecture
Gene Organization
The ATG17 gene spans approximately 40 kb on chromosome 8q11.23 and consists of 46 exons encoding a 1,524 amino acid protein with a molecular weight of approximately 200 kDa. The gene exhibits broad tissue expression with particularly high levels in the brain, heart, and skeletal muscle.
Protein Domains and Structure
The RB1CC1/FIP200 protein contains several critical functional domains[@kourtis2021]:
| Domain | Position | Function |
|--------|----------|----------|
| N-terminal coiled-coil domain | 1-400 | Homodimerization, ULK1/2 binding |
| FIP200 interaction domain | 400-800 | Self-association, complex formation |
| ATG101 binding region | 800-1100 | ATG101 recruitment |
| C-terminal focal adhesion targeting (FAT) domain | 1400-1524 | Subcellular localization |
| LC3-interacting region (LIR) | Multiple | Selective autophagy receptor binding |
The protein functions as a homodimer through its N-terminal coiled-coil domains, creating a elongated dimeric structure that serves as a platform for complex assembly. The multiple LIR motifs enable interaction with various autophagy receptors during selective autophagy processes.
Homology and Evolution
While yeast Atg17 is a smaller 37 kDa protein, mammalian RB1CC1/FIP200 represents a functionally conserved ortholog with additional domains acquired during evolution. The core scaffolding function is conserved, but mammalian RB1CC1 has acquired additional regulatory functions through protein-protein interactions[@mizushima2010].
The ULK1 Complex: Architecture and Function
Complex Composition
ATG17/RB1CC1 forms the central scaffold of the ULK1 complex, which consists of four core components[@itakura2012][@ganley2013]:
ULK1 (or ULK2): Serine/threonine kinase that initiates autophagy signaling
ATG13: Regulatory subunit that bridges ULK1 to ATG17
ATG17/RB1CC1/FIP200: Scaffold protein providing structural framework
ATG101: Stabilizing subunit that binds ATG13The complex has a stoichiometry of 1:1:2:1 for ULK1:ATG13:ATG17:ATG101, with ATG17 forming a dimer that provides two binding sites for ULK1-ATG13 dimers.
Initiation Mechanism
The ULK1 complex responds to cellular nutrient status through two primary regulatory pathways[@kim2021]:
mTORC1 Inhibition Pathway:
- Under nutrient-rich conditions, mTORC1 phosphorylates ULK1 and ATG13, maintaining the complex in an inactive state
- Upon nutrient withdrawal, mTORC1 dissociates, allowing ULK1 auto-activation
- ULK1 phosphorylates multiple downstream targets to initiate autophagy
AMPK Activation Pathway:
- Energy stress activates AMPK, which directly phosphorylates ULK1 at multiple sites
- AMPK activation occurs in parallel with mTORC1 inhibition
- This provides a second independent activation signal
Membrane Recruitment
Once activated, the ULK1 complex translocates to the phagophore assembly site (PAS), where ATG17 plays a critical scaffolding role[@nixon2020]:
VPS34 Complex Recruitment: ATG17 directly interacts with the class III PI3K complex (BECN1-VPS34-VPS15), recruiting it to the nascent phagophore
PI3P Production: VPS34 generates phosphatidylinositol 3-phosphate (PI3P) at the PAS
Membrane Expansion: PI3P-positive membranes expand as the isolation membrane (phagophore)LC3 Lipidation
ATG17 coordinates with the ATG12-ATG5-ATG16L1 conjugation system to facilitate LC3 lipidation:
- ATG17 recruits ATG16L1 to the expanding phagophore
- LC3 (MAP1LC3A/B) is conjugated to phosphatidylethanolamine
- Lipidated LC3 marks the growing autophagosome and recruits cargo receptors
Closure and Maturation
The complex remains associated with the expanding phagophore until closure:
- ATG17 helps orchestrate the final membrane sealing event
- The mature autophagosome then fuses with lysosomes
- ATG17 is not required for late-stage fusion events
Autophagy in Neurodegeneration
Alzheimer's Disease
Autophagy is profoundly impaired in Alzheimer's disease, and ATG17 dysfunction contributes to disease pathogenesis through multiple mechanisms[@nixon2020][@urschke2022]:
Amyloid-β Clearance:
- Impaired ATG17 function reduces autophagic clearance of amyloid-β
- Aβ accumulates in autophagic vacuoles within neurons
- This creates a vicious cycle where Aβ further inhibits autophagy
Tau Pathology:
- Hyperphosphorylated tau disrupts autophagy through multiple mechanisms
- ATG17 expression is reduced in AD brain
- Restoring ATG17 function may enhance tau clearance
Neuronal Vulnerability:
- Neurons are particularly dependent on autophagy due to their post-mitotic state
- Accumulation of damaged proteins and organelles leads to proteostasis collapse
- Autophagy enhancement is a therapeutic target
Parkinson's Disease
ATG17 is critical for mitophagy—the selective autophagy of damaged mitochondria[@tamara2022]:
PINK1-PARKIN Pathway:
- Mitochondrial damage stabilizes PINK1 on the outer membrane
- PINK1 phosphorylates ubiquitin and PARKIN
- Phospho-ubiquitin chains recruit autophagy receptors
- ATG17 coordinates autophagosome formation around damaged mitochondria
Dopaminergic Neuron Survival:
- PD neurons are particularly vulnerable to mitochondrial dysfunction
- Impaired mitophagy leads to accumulation of dysfunctional mitochondria
- Enhancing ATG17-mediated mitophagy may protect dopaminergic neurons
Therapeutic Implications:
- ATG17 expression is reduced in PD brain
- Small molecules enhancing ULK1 complex function are under development
- Gene therapy approaches to boost ATG17 are being explored
Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Mutations in ATG17/RB1CC1 have been linked to ALS and FTD[@yamamoto2020]:
FIP200 Mutations:
- Rare missense mutations in RB1CC1 are associated with familial ALS
- These mutations impair autophagy function
- TDP-43 pathology may be exacerbated by autophagy dysfunction
Therapeutic Targeting:
- Enhancing autophagy may help clear TDP-43 aggregates
- AAV-mediated ATG17 overexpression is being explored
- Small molecule activators of the ULK1 complex are in development
Interaction Network
ATG17 interacts with multiple proteins to coordinate autophagy initiation[@mari2020]:
| Protein | Interaction Type | Functional Role |
|---------|------------------|-----------------|
| ULK1 | Direct binding | Kinase activation, complex assembly |
| ULK2 | Direct binding | Redundant kinase function |
| ATG13 | Direct binding | Regulatory subunit |
| ATG101 | Direct binding | Complex stabilization |
| VPS34 | Indirect via recruitment | PI3K recruitment |
| BECN1 | Indirect via recruitment | PI3K complex component |
| RB1 | Direct binding | Tumor suppressor function |
| FAK | Direct binding | Cell adhesion signaling |
| p53 | Transcriptional regulation | Tumor suppression |
Expression and Regulation
Brain Distribution
ATG17 is widely expressed in the central nervous system:
| Brain Region | Expression Level | Significance |
|--------------|------------------|---------------|
| Cerebral Cortex | High | High neuronal density, elevated autophagy demand |
| Hippocampus | High | Memory formation, CA1 particularly vulnerable |
| Basal Ganglia | High | Dopaminergic neuron maintenance |
| Cerebellum | High | Purkinje cell function |
| Brainstem | Moderate | Vital function maintenance |
| White Matter | Lower | Lower metabolic activity |
Cellular Expression
- Neurons: High expression; particularly important for protein homeostasis
- Astrocytes: Moderate expression; supports neuronal metabolism
- Microglia: Moderate expression; involved in phagocytosis
- Oligodendrocytes: Lower expression
Regulatory Mechanisms
ATG17 expression and activity are regulated at multiple levels:
Transcriptional Regulation: p53 positively regulates ATG17 expression
Post-translational Modification: Phosphorylation by ULK1 and other kinases
Protein Stability: Regulated by the ubiquitin-proteasome system
Subcellular Localization: Relocalizes to autophagy sites upon activationTherapeutic Implications
Pharmacological Approaches
Several strategies to enhance ATG17 function are under development[@martinez2016]:
ULK1 Kinase Activators:
- Small molecules that activate ULK1 upstream of ATG17
- May enhance autophagy initiation
- Currently in preclinical development
mTOR Inhibitors:
- Rapamycin and analogues inhibit mTORC1
- Release ULK1 complex from inhibition
- FDA-approved for other indications
Autophagy Enhancers:
- Natural compounds (e.g., curcumin, resveratrol) enhance autophagy
- May act partially through ATG17 pathway
- Clinical trials in AD/PD ongoing
Gene Therapy Approaches
- AAV-mediated ATG17 overexpression
- CRISPR-based gene editing to enhance expression
- miRNA antagonists to reduce inhibitory miRNAs
Combination Strategies
- Autophagy enhancement combined with Aβ/tau targeting
- Multi-target approaches for synergistic effects
- Personalized medicine based on genotype
Key Publications
[Mizushima et al., The role of the Atg1/ULK1 complex in autophagy initiation. Autophagy. 2023](https://pubmed.ncbi.nlm.nih.gov/36720654/)
[Rubinsztein et al., Autophagy and neurodegenerative disease. Cell. 2022](https://pubmed.ncbi.nlm.nih.gov/35472301/)
[Kourtis & Tavernarakis, Cellular stress response pathways and autophagy. J Mol Biol. 2021](https://pubmed.ncbi.nlm.nih.gov/33798458/)
[Nixon et al., The involvement of autophagy in Alzheimer's disease. Nat Rev Neurol. 2020](https://pubmed.ncbi.nlm.nih.gov/32778754/)
[Levine et al., Autophagy in neural function and disease. Neuron. 2019](https://pubmed.ncbi.nlm.nih.gov/30609405/)
[Itakura et al., ULK1 complex - autophagy initiation. Mol Biol Cell. 2012](https://pubmed.ncbi.nlm.nih.gov/22855437/)
[Ganley et al., ULK1 complex composition and function. J Cell Biol. 2013](https://pubmed.ncbi.nlm.nih.gov/24252615/)
[Yamamoto et al., FIP200 mutations in ALS/FTD. Nat Neurosci. 2020](https://pubmed.ncbi.nlm.nih.gov/33168966/)
[Tamara et al., ATG17 in mitophagy and Parkinson's disease. J Neurosci. 2022](https://pubmed.ncbi.nlm.nih.gov/35697652/)
[Urschke et al., Autophagy modulation as therapeutic strategy in AD. Brain. 2022](https://pubmed.ncbi.nlm.nih.gov/35820619/)See Also
- [ATG5 Gene](/genes/ATG5) - Autophagy conjugation system
- [ATG7 Gene](/genes/atg7) - Autophagy conjugation system
- [ULK1 Gene](/genes/ULK1) - Kinase in autophagy initiation
- [Autophagy Pathway](/mechanisms/autophagy-lysosome-pathway) - Autophagy mechanisms
- [Mitophagy Pathway](/mechanisms/mitophagy) - Mitochondrial autophagy
- [Alzheimer's Disease](/diseases/alzheimers-disease) - AD overview
- [Parkinson's Disease](/diseases/parkinsons-disease) - PD overview
External Links
- [GeneCards - RB1CC1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=RB1CC1)
- [UniProt - RB1CC1](https://www.uniprot.org/uniprot/Q8TF72)
- [NCBI Gene - RB1CC1](https://www.ncbi.nlm.nih.gov/gene/9881)
- [OMIM - RB1CC1](https://www.omim.org/entry/604791)
- [Ensembl - RB1CC1](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000055118)
- [Allen Brain Atlas - RB1CC1](https://human.brain-map.org/microarray/search/show?search_term=RB1CC1)
Pathway Diagram
The following diagram shows the key molecular relationships involving ATG17 Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)